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Abstract
Background: Malignant pleural effusion (MPE) occurs at a terminal stage of cancer, and related symptoms may
considerably reduce a patient’s respiratory function and quality of life. We assessed the benefit of simple
intrapleural hyperthermia (SIH) during thoracoscopic exploration for MPE.
Methods: We conducted a retrospective review of 34 patients underwent thoracoscopic exploration and SIH
procedures for MPE between April, 2009 and July, 2014 at our institution. One month after removal of the tube,
therapeutic efficacy was evaluated, calculating response rates and recurrence rate.
Results: In this cohort (male, 11; female, 23; average age, 54.2 ± 12.7 years), the most frequent primary cancers were
breast (n = 11, 32.4 %), lung (n = 10, 29.4 %), and ovarian (n = 6, 17.6 %). Therapeutic response (ie, presence of
pleural effusion) was assessed 1 month after chest tube removal, with 19 (55.9 %) showing complete response (CR),
9 (26.5 %) showing partial response (PR), and non-response (NR) seen in 6 (17.6 %). The combined (CR + PR)
response rate was 82.4 %. During follow-up, there were seven instances of recurrence, requiring repeat drainage.
Three- and 7-month recurrence-free rates were 86.9 and 73.9 %, respectively. No postoperative respiratory
complications or fever developed. Early death within 3 months from progression of primary cancer was identified
as a risk factor in patients of NR status (HR = 18.36, p = 0.043).
Conclusions: If thoracoscopic exploration is indicated for MPE, SIH is a safe and effective management alternative
in patients whose primary malignancy is not rapidly progressing.
Keywords: Pleural effusion, Malignant, Thoracoscopy, Pleurodesis
Background
Malignant pleural effusion (MPE) often occurs in the
course of malignancies and may impair pulmonary
function. Quality of life is also diminished due to symp-
toms (ie, dyspnea, pain, cough, etc.) [1]. Various cancers
(lung, breast, or ovarian) and hematogenous neoplasms
(lymphomas) often culminate in MPE, although in many
instances, the source is unknown [1, 2]. However, lung
and breast cancers are implicated in > 50 % of such
cases, according to reports [3].
MPE develops when malignant cells metastasize to
pleura, but diagnostic cells may or may not be detectable
in pleural fluid. On the other hand, paramalignant
pleural effusion does occur in the course of some can-
cers and is not easily differentiated from MPE [1, 2]. For
any pleural effusion found in a patient with confirmed
malignancy, fluid cytology is normally requested. If cy-
tology is unproductive, pleural biopsy may be needed,
usually via diagnostic thoracoscopic exploration. Pleural
biopsy is sometimes the only recourse in instances
where primary tumors are unknown [4, 5].
Thoracoscopic exploration enables direct identification
of pleural nodules, with biopsy of pleura and lung for
pathologic confirmation. Even if MPE is documented,
thoracoscopic exploration also serves a therapeutic pur-
pose, allowing more effective drainage of any loculated
fluid. When done for above reasons, pleurodesis is typic-
ally performed as well, instilling sclerosing agents at the
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close of exploration. The latter is especially warranted in
patients faced with long-term tube placement for recur-
rent pleural effusion.
Although talc is generally the most effective agent for
pleurodesis, serious complications, such as acute respira-
tory distress syndrome (ARDS) and systemic inflamma-
tion, may result. Graded talc is used in the United States
and in Europe to minimize complications [6] However,
availability is limited in Asia. Other agents, such as doxy-
cycline, bleomycin, iodopovidone, and silver nitrite, are
less effective than talc, and related studies are few [7].
Some reports indicate that tumor cell survival may be
reduced by exposure to solutions at supraphysiologic
temperatures [8–11]. Intrapleural hyperthermic chemo-
therapy has been used to treat pleural malignancy or
pleural metastasis of lung cancer. By combining a che-
motherapeutic agent with a hyperthermic solution, sur-
vival times may actually be increased [12–15]. However,
almost no accounts to date describe the use of simple
intrapleural hyperthermia (SIH) for MPE.
Consequently, we attempted to confirm the benefits of
SIH in patients where MPE was diagnosed or strongly
suspected, necessitating thoracoscopic exploration for
diagnosis or for drainage of fluid. Our aim was to
achieve immediate symptom improvement and maintain
stability long-term, avoiding recurrences. Other objec-
tives were minimization of complications, shortening of
hospitalization periods, and cost-effectiveness [1].
Methods
Patients
Among 45 patients who underwent SIH procedures after
thoracoscopic exploration in the period between April,
2009 and July, 2014, three patients were lost to follow-
up, four patients had pleural metastasis without pleural
effusion, and four patients had benign pleural biopsies
with no primary cancers. The latter were excluded, leav-
ing 34 patients who qualified for retrospective chart re-
view. In all patients, pleural effusion was confirmed by
computed tomography (CT) of the chest. Thoracoscopic
pleural biopsy was done in patients with medical histor-
ies of primary cancers and suspected pleural metastases
or with no primary cancer by history but with suspected
MPE. In instances where MPE was already confirmed by
fluid cytology, thoracoscopic drainage of loculated pleural
fluid was opted. SIH was conducted following thoraco-
scopic procedures. All of the patients consented the pro-
cedure before operation. The study was approved by the
institutional Review Board of Seoul St. Mary’s Hospital
(The Catholic University of Korea)
Surgical technique
Under general anesthesia and with patients in lateral
decubitus position, two ports (10 mm and 5 mm) were
created at points where pleural effusions were most
voluminous. After completing thoracoscopic pleural bi-
opsy or pleurolysis (for loculated effusion), a chest tube
was inserted through one port, reaching the deepest
point in thoracic cavity, and SIH was conducted. With
the thoracoscope deployed through the other port, nor-
mal saline (48 °C) was continuously injected through
the chest tube under observation (Fig. 1). We used 48 °C
saline because of rapid decline of saline temperature due
to low velocity of manual infusion flow. Once the thoracic
cavity was completely filled with saline, the thoracoscope
was removed, leaving the port open for natural drainage
of saline. During this time, a bar thermometer inserted
through thoracoscopic port served to continuously moni-
tor temperature inside the thoracic cavity (Fig. 2). Our
SIH method involved frequent injection of physiologic
saline solution (48 °C, 30 min) into thoracic cavity via
chest tube, keeping pleural temperature above 42 °C.
After 30 min, all intrathoracic saline solution was re-
moved by suction, and the wound was closed with a
chest tube in place.
Chest tube removal
Tubes remained in position for 2 days at minimum and
were removed once the amount of drainage fluid was
< 150 ml in a 24-h period.
Treatment efficacy
Following all operative procedures, plain x-ray films of
the chest were obtained daily. Chest x-ray and CT im-
aging were also done periodically after hospital discharge
to monitor pleural effusion status. Criteria (WHO) for
evaluating therapeutic effects in patients with solid tu-
mors were modified to assess outcomes of treatment in
this setting; Complete response (CR), partial response
(PR), and non-response (NR) corresponded with
Fig. 1 Normal saline (48 °C) injection through the chest tube under
thoracoscopic observation
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absence of effusion for > 4 weeks after treatment, 50 %
reduction in effusion for > 4 weeks after treatment, and
no reduction in pleural effusion, respectively [16]. Any
drainage required in follow-up was defined as recur-
rence [17].
Statistical analysis
Data were expressed as mean values ± standard deviation
(SD) or percentages. Operative mortality was defined as
in-hospital mortality or death within 30 days after proce-
dures. Response rate was calculated as the ratio between
combined responses (CR + PR) and total patient count.
Recurrence-free rate was calculated for specified time in-
tervals, applying Kaplan-Meier method. Logistic regres-
sion analysis was used to determine factors linked with
patient non-response (NR). Statistical significance was
set at p < 0.05.
Results
A total of 34 patients (mean age, 54.2 ± 2.7 years; male-
to-female ratio, 11:23) with MPE submitted to thoraco-
scopic exploration at our institution. Breast (n = 11,
32.4 %), lung (n = 10, 29.4 %), and ovary (n = 6, 17.6 %)
were the most common primary tumor sites. The re-
mainder (n = 7, 20.6 %) included two malignancies of
unknown origin, two hepatic cancers, and one instance
each of primary renal, peritoneal, and pleura (meso-
thelioma) neoplasms. Procedures performed were uni-
lateral (right: n = 16, 47.1 %; left: n = 10, 29.4 %) or
bilateral (n = 8, 23.5 %). In 24 patients (70.6 %), malig-
nancy was diagnosed via pleural biopsy or pleural fluid
cytology. Malignancy was unproven in the other 10 pa-
tients (29.4 %), despite primary tumors in advanced stages
and persistent pleural effusion. Most patients (n = 30,
88.2 %) required pleurocentesis prior to surgery (Table 1).
Thoracoscopic exploration was regularly performed in
advance of SIH, which was sustained at 42°-45 °C for
30 min. Temperature of thoracic esophagus was mea-
sured during all operations, with maximum levels fall-
ing below 40 °C. Mean body temperature 30 min after
surgery was 36.6 ± 0.3 °C, and no patients were febrile
on the first postoperative day. Blood pressures (BP)
taken mid-procedure were stable. Although mean heart
rate (HR) was 99.5 ± 22.0 beats/min, HR < 100 beats/min
were recorded within 30 min after all procedures. Chest
tubes were kept in place for a minimum of 2 days postop-
eratively but were removed once drainage was < 150 ml/
24 h. Mean duration of chest tube drainage was 9.2 ±
4.8 days. Patients were discharged from the hospital on
the days following chest tube removal, if additional treat-
ment for primary malignancy was not required.
No postoperative respiratory complications or fever
were recorded. One patient with ovarian cancer and re-
current MPE died postoperatively on Day 35. In this in-
stance, the chest tube was removed on Day 14 after SIH,
but carcinomatosis peritonei was unrelenting and aspir-
ation pneumonia developed on Day 27, leading to death.
Pleural effusions were confirmed by x-ray or CT of the
chest one month after chest tube removal. There were
19 patients (55.9 %) of CR status, 9 patients (26.5 %) of
PR status, and 6 patients (17.6 %) of NR status. The
combined (CR + PR) response rate was 82.4 %. Mean
follow-up period overall was 382.6 days (range, 35–1885
days). Seven patients (CR, 1; PR, 1; NR, 5) underwent
Fig. 2 Leaving the port open for natural drainage of saline and
continuously monitoring the temperature of effluent fluid using
bar thermometer
Table 1 Patients characteristics (n = 34)
Characteristic Value
Age, years (mean ± SD) 54.2 ± 12.7
Gender, n (%)
Male 11 (32.4 %)
Female 23 (67.6 %)
Primary malignancy, n (%)
Lung 10 (29.4 %)
Breast 11 (32.4 %)
Ovarian 6 (17.6 %)
Other 7 (20.6 %)
Laterality, n (%)
Right 16 (47.1 %)
Left 10 (29.4 %)
Bilateral 8 (23.5 %)
Histologic confirmation, n (%)
Confirmed MPE 24 (70.6 %)
Unconfirmed MPE 10 (29.4 %)
Preoperative pleural drainage, n (%) 30 (88.2 %)
SD = standard deviation
MPE =Malignant pleural effusion
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repeat drainage of pleural effusions (recurrent MPE)
during follow-up. Kaplan-Meier method was applied to
calculate recurrence-free rate (86.9 % at 3 months;
73.9 % at 7 months) (Table 2). Logistic regression ana-
lysis was used to evaluate risk factor of NR. In multivari-
ate analysis, along with age, malignant fluid cytology,
and type of primary cancer, early death within 3 months
showed a significant association with NR status (HR =
18.36; p = 0.043) (Table 3).
Discussion
Patients with MPE often require management, given
their declining general condition and quality of life.
Most of their symptoms may be temporarily alleviated
by pleurocentesis, and in instances where repeated drain-
age is required, other methods (eg, pleurodesis, indwelling
catheter, and pleuroperitoneal shunt) are useful [3]. Al-
though pleurodesis has been the preferred treatment, in-
corporating talc as a sclerosing agent to obliterate the
pleural space [1, 2], an indwelling tunneled pleural catheter
(TPC) is now used in many countries. Unlike pleurodesis,
chemotherapy is not delayed by TPC use, so hospital stays
are reduced; and results have been durable, similar to those
achieved with talc [5, 18–20]. However, the inconvenience
of managing a catheter at home, concerns of catheter-
related infection, and less complete obstruction of re-
accumulating fluid are drawbacks. As a rule, Western
patients are more receptive to in-home management,
whereas Korean patients are more inclined to be fully
treated as inpatients and make less use of TPCs.
As the most effective agent available for pleurodesis
[1, 3, 21, 22], talc may be administered through thora-
coscopic poudrage or as a slurry injected via chest tube.
A higher success rate is attached to a thoracoscopic ap-
proach [1]. Small-sized talc particles tend to dissemin-
ate systemically, often provoking an inflammatory
response. Hence, the use of graded talc (with small par-
ticles removed) is advised [1, 2, 6, 23], although this
product is not readily available in many countries, in-
cluding Korea.
A number of talc alternatives, such as doxycycline,
povidone iodine, and antineoplastic agents, have been
tried without success at our facility. However, very few
reports substantiate their efficacy, and related complica-
tions, such as pain, fever, and systemic inflammation,
were no fewer when compared with talc. Thus, they are
not considered acceptable for pleurodesis [1, 24].
Direct injection of chemotherapeutic agents into
pleural metastases is also done at times for local con-
trol of malignancy. Reports have indicated that apop-
tosis of tumor cells is accelerated by exposure to
supraphysiologic hyperthermic solution [8–11]. Until
recently, the observed survival benefits were attributed to
a combination of hyperthermic solution and chemothera-
peutic agent injected into the thoracic cavity [12–15, 25].
However, such results were assured by performing local
treatment under conditions of pleural metastasis exclu-
sively (without systemic dissemination), and this ap-
proach has never been utilized to manage MPE. In our
hospital, such treatments are for palliation only, so a
trial of hyperthermic saline alone (without chemother-
apy) was initiated for MPE management. Although
study subjects had persistent pleural effusions, diagno-
ses were unconfirmed. Thoracoscopic surgery was
therefore required to obtain pleural biopsies and/or
drain loculated fluid. Ultimately, SIH (30 min) was con-
ducted following thoracoscopic exploration.
MPE treatment outcomes have been evaluated in vari-
ous ways by a number of researchers. Checking for re-
currence of pleural effusion on follow-up chest x-ray or
CT imaging is the usual means of assessing therapeutic
response. The calculated recurrence rate is also based on
the need to re-insert a chest tube or catheter to drain a
growing pleural effusion [7]. For our purposes, we calcu-
lated CR, PR, and NR by evaluating treatment response
1 month after chest tube removal. Recurrence was as-
sumed if drainage of pleural fluid was required during
follow-up.
Our approach yielded satisfactory therapeutic effect,
with an overall response rate of 82.4 % and recurrence-
free rates of 90 % and 70 % at 3 and 7 months, respect-
ively. Comparisons admittedly were imprecise, owing to
the fact that assessment of response to treatment dif-
fered across studies. Assuming a response rate of 80-
90 % for thoracoscopic talc poudrage and 60-80 % for
talc slurry, the efficacy shown in this study was on par
with other reports [7].
Table 2 Surgical outcomes
n (%)
Postoperative complications
Respiratory events 0 (0 %)
Fever 0 (0 %)
Operative mortality 1 (3 %)
Response rates
Complete (CR) 19 (55.9 %)
Partial (PR) 9 (26.5 %)
None (NR) 6 (17.6 %)
Combined (CR + PR) 28 (82.4 %)
Recurrence rate 7 (20.6 %)
3-month recurrence-free survival 86.9 %
4-month recurrence-free survival 82.9 %
7-month recurrence-free survival 73.7 %
CR = complete response
PR = partial response
NR = no response
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In the course of this study, no major complications,
such as respiratory events and fever, were encountered,
and there were no minor complications, except for pain
early-on at chest tube insertion sites. Accordingly, SIH
appears much safer than pleurodesis, showing far fewer
problems than pleurodesis in terms of systemic inflam-
mation, respiratory complications, and intense pain.
Nevertheless, intensive monitoring is critical to main-
tain intrathoracic operative temperatures > 42 °C, while
closely monitoring BP, HR, and EKG and keeping the
patient’s body temperature <40 °C.
Other than the cost of thoracoscopic exploration, no
added expense accrued for SIH. A solution of saline (at
48 °C) for simple, manual injection into thoracic cavity
via chest tube was the sole requirement. However, chest
tubes were left in place for an average of 9.2 ± 4.8 days,
which is about 3–4 days longer than times reported else-
where for thoracoscopic talc pleurodesis [5, 26, 27]. This
was attributable in part to surgeons insisting that chest
tubes be removed as late as possible postoperatively.
The National Health Service of Korea also enables low-
cost hospitalization, encouraging longer stays. Further
study is needed to directly compare thoracoscopic SIH
with pleurodesis.
There were six patients of NR status and seven pa-
tients with recurrences. Pleural drainage was not re-
peated in one NR patient, who was not viewed as a
recurrence. This patient had non-small cell lung cancer,
with a left-sided MPE and malignant pericardial effusion.
Chemotherapy was given for the primary cancer, once
symptoms abated after thoracoscopic pericardial window
and left-sided SIH. Unfortunately, both pericardial effu-
sion and MPE recurred after 1 month. The patient was
closely monitored without further drainage, given that
the volume of fluid was lower than its initial level and
did not increase further. Drainage of the pericardial effu-
sion continued, but this patient died 44 days after sur-
gery, suffering from acute renal failure and generalized
edema.
Among the seven patients with recurrences, five had
NR status, with one each achieving CR and PR. The pa-
tient of CR status underwent repeat bilateral drainage of
pleural effusions, which recurred 6 months after SIH
treatment for peritoneal cancer. At that time, the pri-
mary cancer had also recurred. Death occurred 2 months
after re-drainage due to disease progression, although
chemotherapy of the primary tumor was ongoing. The
patient of PR status had common bile duct cancer and
underwent repeat bilateral drainage of pleural effusions,
which recurred 4 months after temporary improvement
through SIH. The primary tumor was progressive, cul-
minating in death 1 month after recurrence. All 17 pa-
tient mortalities during follow-up resulted from disease
progression. Among the deaths were 13 responders to
SIH, only two of which (15.4 %) experienced recurrences
of pleural effusion. Recurrent effusions were actually few
in number, underscoring that effects of SIH are not
undermined by disease progression.
Five patients died early (within 3 months) due to dis-
ease progression—three of NR and two of PR status.
None of the deaths were treatment-related. Risk factor
analysis confirmed that NR status was a significant
marker of rapid progression and early death. In other
words, the efficacy of SIH is diminished by rapidly ad-
vancing disease, with life expectancy of < 3 months.
Several limitations of this study are acknowledged,
the first being a retrospective analysis of operative re-
sults in a relatively small patient sampling at single cen-
ter. Future studies with more cases may provide more
accurate results, and a multicenter randomized trial
may be required to validate our results. In addition,
histologic studies after SIH were not done, and the
basis (biologic and physiologic) for pleural hyperther-
mic effects remains unexplained. Although some have
argued that tumor cells undergo apoptosis due to
hyperthermia (shown in animal experimentation), this
claim could not be corroborated here. In some patients
for whom pleural biopsy was done intraoperatively
(once or twice), no morphologic differences were de-
tected in comparing histologic features of pleura before
and after surgery. Undoubtedly, time is needed for
apoptotic manifestations to materialize, so this observa-
tion is not unexpected. Still, it was not appropriate to
re-biopsy patients under palliative treatment, merely to
confirm tissue changes. Finally, evaluating the superior-
ity of this therapy relative to other treatment methods
proved difficult. Each study engaged a slightly different
method, with no standard measures of treatment effect.
A multicenter prospective study of MPE management
might remedy this shortcoming.
Table 3 Risk factors for non-response to treatment (multivariate analysis)
Factors Hazard ratio 95 % confidence interval P value
Age 1.030 0.940–1.129 0.522
Primary cancer 1.065 0.334–3.403 0.915
Malignant cells in pleural fluid 5.830 0.370–91.839 0.210
Death within 3 months 18.360 1.098–306.912 0.043
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Conclusions
Although there are many ways to manage MPE, practical
considerations and substantial side effects may restrict
their usage. In patients for whom thoracoscopic explor-
ation is indicated, SIH is one means of effectively man-
aging MPE, provided the primary malignancy is not
rapidly progressing. SIH is less rigorous than pleurod-
esis, with fewer side effects.
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